Sign in

Lost your password?
(close)

Heptares Therapeutics Ltd

Last updated: 13.02.2014

Address: 6 Henrietta Street
London
WC2E 8PU

Tel: +44 (0)20 7557 7500

Web: http://www.mvmlifescience.com/

Company description

Heptares is a drug discovery company creating new medicines targeting G-protein-coupled receptors (GPCRs).

The Company is currently leveraging its GPCR expertise and proprietary StaR® technology to build a pipeline of best-in-class and first-in-class GPCR-targeted medicines for the treatment of CNS, metabolic and other diseases.

Heptares Therapeutics Ltd has already four-year collaboration with AstraZeneca (2011), where they focused on developing small molecule and antibody candidates targeting specific GPCRs linked to CNS/pain, CV/metabolic and inflammatory disorders.

Also, an approximately $100 million drug discovery collaboration with Takeda (2011) focused on a GPCR linked to CNS disorders.

Moreover, $200 million alliance with the Novartis Option Fund (2009) focused on single GPCR target of strategic interest to Novartis. Novartis and Heptares jointly announced the successful first-ever stabilisation of this previously intractable GPCR using the Heptares technology.

Products and services

Heptares Therapeutics Ltd deploys structure-based drug discovery techniques to identify potent and selective drug candidates to previously undruggable targets. They develop small molecule and antibody candidates targeting specific GPCRs linked to CNS/pain, CV/metabolic and inflammatory disorders.

Related

We use cookies to ensure that we give you the best experience on our site. For more info click here